BIOMAT Database Logo BIOMAT Database Logo

FR901724, a novel anti-human immunodeficiency virus (HIV) peptide produced by Streptomyces, shows synergistic antiviral activities with HIV protease inhibitor and 2',3'-dideoxynucleosides. 1996

H Nakashima, and K Ichiyama, and K Inazawa, and M Ito, and H Hayashi, and Y Nishihara, and E Tsujii, and T Kino
Department of Microbiology, Yamanashi Medical University, Japan.

A novel tricyclic 21-amino-acid peptide, FR901724, was isolated from the cultured broth of Streptomyces sp. No. 73264. This peptide appears to possess potent anti-human immunodeficiency virus (HIV) activity in vitro and might represent a lead to a new class of anti-HIV agents; it qualifies as an HIV-cell fusion inhibitor because of its weak inhibition of virus-cell binding and strong inhibition of syncytium formation. From the time-of-addition experiments, the mode of action of FR901724 was found to definitely differ from that of KNI-272, a peptide mimetic allophenylnorstatine-derivative HIV protease inhibitor. FR901724 appears to interact with a stage of the virus replicative cycle that may well correspond to virus-cell fusion. We also found that FR901724 was synergistic or had a strong tendency toward synergism when combined with other antiviral drugs, such as KNI-272, AZT, ddI and dextran sulfate.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010456 Peptides, Cyclic Peptides whose amino acid residues are linked together forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS; some are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). Circular Peptide,Cyclic Peptide,Cyclic Peptides,Cyclopeptide,Orbitide,Circular Peptides,Cyclopeptides,Orbitides,Peptide, Circular,Peptide, Cyclic,Peptides, Circular
D011134 Polysaccharides Long chain polymeric CARBOHYDRATES composed of MONOSACCHARIDES linked by glycosidic bonds. Glycan,Glycans,Polysaccharide
D003588 Cytopathogenic Effect, Viral Visible morphologic changes in cells infected with viruses. It includes shutdown of cellular RNA and protein synthesis, cell fusion, release of lysosomal enzymes, changes in cell membrane permeability, diffuse changes in intracellular structures, presence of viral inclusion bodies, and chromosomal aberrations. It excludes malignant transformation, which is CELL TRANSFORMATION, VIRAL. Viral cytopathogenic effects provide a valuable method for identifying and classifying the infecting viruses. Cytopathic Effect, Viral,Viral Cytopathogenic Effect,Cytopathic Effects, Viral,Cytopathogenic Effects, Viral,Effect, Viral Cytopathic,Effect, Viral Cytopathogenic,Effects, Viral Cytopathic,Effects, Viral Cytopathogenic,Viral Cytopathic Effect,Viral Cytopathic Effects,Viral Cytopathogenic Effects
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013302 Streptomyces A genus of bacteria that form a nonfragmented aerial mycelium. Many species have been identified with some being pathogenic. This genus is responsible for producing a majority of the ANTI-BACTERIAL AGENTS of practical value.
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings

Related Publications

H Nakashima, and K Ichiyama, and K Inazawa, and M Ito, and H Hayashi, and Y Nishihara, and E Tsujii, and T Kino
In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor.
December 1993, Antimicrobial agents and chemotherapy,
H Nakashima, and K Ichiyama, and K Inazawa, and M Ito, and H Hayashi, and Y Nishihara, and E Tsujii, and T Kino
NP-06: a novel anti-human immunodeficiency virus polypeptide produced by a Streptomyces species.
October 1995, Antimicrobial agents and chemotherapy,
H Nakashima, and K Ichiyama, and K Inazawa, and M Ito, and H Hayashi, and Y Nishihara, and E Tsujii, and T Kino
1H NMR study of the sugar pucker of 2',3'-dideoxynucleosides with anti-human immunodeficiency virus (HIV) activity.
August 1991, Biochemical and biophysical research communications,
H Nakashima, and K Ichiyama, and K Inazawa, and M Ito, and H Hayashi, and Y Nishihara, and E Tsujii, and T Kino
2-halo-2',3'-dideoxyadenosines: metabolically stable dideoxynucleosides with activity against the human immunodeficiency virus (HIV).
January 1989, Advances in experimental medicine and biology,
H Nakashima, and K Ichiyama, and K Inazawa, and M Ito, and H Hayashi, and Y Nishihara, and E Tsujii, and T Kino
Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.
October 1994, Molecular pharmacology,
H Nakashima, and K Ichiyama, and K Inazawa, and M Ito, and H Hayashi, and Y Nishihara, and E Tsujii, and T Kino
Synthesis and antiviral activity of novel fluorinated 2',3'-dideoxynucleosides.
January 2004, Nucleosides, nucleotides & nucleic acids,
H Nakashima, and K Ichiyama, and K Inazawa, and M Ito, and H Hayashi, and Y Nishihara, and E Tsujii, and T Kino
Mer-N5075A, a potential HIV-1 protease inhibitor, produced by Streptomyces chromofuscus.
October 1993, The Journal of antibiotics,
H Nakashima, and K Ichiyama, and K Inazawa, and M Ito, and H Hayashi, and Y Nishihara, and E Tsujii, and T Kino
Potential prodrug derivatives of 2',3'-didehydro-2',3'-dideoxynucleosides. Preparations and antiviral activities.
July 1992, Journal of medicinal chemistry,
H Nakashima, and K Ichiyama, and K Inazawa, and M Ito, and H Hayashi, and Y Nishihara, and E Tsujii, and T Kino
Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease.
April 2002, Antiviral research,
H Nakashima, and K Ichiyama, and K Inazawa, and M Ito, and H Hayashi, and Y Nishihara, and E Tsujii, and T Kino
In vitro and ex vivo anti-human immunodeficiency virus (HIV) activities of a new water-soluble HIV protease inhibitor, R-87366, containing (2S,3S)-3-amino-2-hydroxy-4-phenylbutanoic acid.
February 1997, Biological & pharmaceutical bulletin,
Copied contents to your clipboard!